Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Local administration of porcine immunomodulatory, chemotactic and angiogenic extracellular vesicles using engineered cardiac scaffolds for myocardial infarction

  • Moron-Font, Miriam
  • Clos-Sansalvador, Marta
  • Calle, Alexandra
  • Morancho Retana, Anna
  • Rosell Novel, Anna
  • Monguió-Tortajada, Marta
  • Prat-Vidal, Cristina
  • Gastelurrutia, Paloma
Ingeniería de tejido cardíaco; Exosomas; Infiltración, Enginyeria de teixits cardíacs; Exosomes; Infiltració, Cardiac tissue engineering; Exosomes; Infiltration, The administration of extracellular vesicles (EV) from mesenchymal stromal cells (MSC) is a promising cell-free nanotherapy for tissue repair after myocardial infarction (MI). However, the optimal EV delivery strategy remains undetermined. Here, we designed a novel MSC-EV delivery, using 3D scaffolds engineered from decellularised cardiac tissue as a cell-free product for cardiac repair. EV from porcine cardiac adipose tissue-derived MSC (cATMSC) were purified by size exclusion chromatography (SEC), functionally analysed and loaded to scaffolds. cATMSC-EV markedly reduced polyclonal proliferation and pro-inflammatory cytokines production (IFNγ, TNFα, IL12p40) of allogeneic PBMC. Moreover, cATMSC-EV recruited outgrowth endothelial cells (OEC) and allogeneic MSC, and promoted angiogenesis. Fluorescently labelled cATMSC-EV were mixed with peptide hydrogel, and were successfully retained in decellularised scaffolds. Then, cATMSC-EV-embedded pericardial scaffolds were administered in vivo over the ischemic myocardium in a pig model of MI. Six days from implantation, the engineered scaffold efficiently integrated into the post-infarcted myocardium. cATMSC-EV were detected within the construct and MI core, and promoted an increase in vascular density and reduction in macrophage and T cell infiltration within the damaged myocardium. The confined administration of multifunctional MSC-EV within an engineered pericardial scaffold ensures local EV dosage and release, and generates a vascularised bioactive niche for cell recruitment, engraftment and modulation of short-term post-ischemic inflammation., This work was supported in part by grants from Fundació la Marató de TV3 (201516-10, 201502-30), the PERIS (SLT002/16/00234) and SGR programmes (2017-SGR-301 REMAR Group, 2017-SGR-1427 and 2017-SGR-483 ICREC Group) from the Generalitat de Catalunya, the Spanish Ministry of Economy and Competitiveness-MICINN (SAF2017-84324-C2-1-R; PID2019-110137RB-I00; PID2019-107145RB-I00), Instituto de Salud Carlos III (PI17/01487, PIC18/00014, ICI19/00039, PI18/00256, PI18/01227, and ICI20/00135), ISCIII-REDinREN (RD16/0009 Feder Funds), Red de Terapia Celular-TerCel (RD16/0011/0006), CIBER Cardiovascular (CB16/11/00403) projects as a part of the Plan Nacional de I + D + I, and it was co-funded by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER), AGAUR (2019PROD00122), Sociedad Española de Cardiología, Societat Catalana de Cardiologia, PCMR[C] and EoI Collaborative Projects on Regenerative Medicine 2019, and Institut Català de Salut (ICS). PG is sponsored by the PERIS (SLT002/16/00209) from the Generalitat de Catalunya. AR is supported by the Miguel Servet program (CPII15/00003) and research grants (PI16/00981) from the Instituto de Salud Carlos III, and co-financed by the European Regional Development Fund. FEB is a researcher from Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, supported by the Health Department of the Catalan Government (Generalitat de Catalunya).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience

  • Vives Armengol, Joaquim
  • Coll, Ruth
  • Gálvez-Montón, Carolina
  • Prat-Vidal, Cristina
  • Gastelurrutia, Paloma
  • Bayes-Genis, Antoni
Medicament de teràpia avançada; Medicament en investigació; Translacional (regulació), Medicamento de terapia avanzada; Medicamento en investigación; Traslacional (regulación), Advanced therapy medicinal product; Investigational medicinal product; Translational (regulation), A systematic and ordered product development program, in compliance with current quality and regulatory standards, increases the likelihood of yielding a successful advanced therapy medicinal product (ATMP) for clinical use as safe and effective therapy. As this is a novel field, little accurate information is available regarding the steps to be followed, and the information to be produced to support the development and use of an ATMP. Notably, successful clinical translation can be somewhat cumbersome for academic researchers. In this article, we have provided a summary of the available information, supported by our experience in Spain throughout the development of an ATMP for myocardial infarction, from the pre-clinical stage to phase I clinical trial approval., This work was supported by the Spanish Cell Therapy Network (TerCel) [RD16/0011/0006 and RD16/0011/0028]; and CIBER Cardiovascular [CB16/11/00403] projects, as a part of the National R&D&I Plan, and was co-funded by the ISCIII-Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (ERDF); the Government of Catalonia: Agency for Management of University and Research Grants (AGAUR) [2017-SGR-483 and 2017-SGR-719], PERIS Program (Health Department) [SLT002/16/00234 and SLT002/16/00209] and CERCA Program; La Caixa Banking Foundation; grants from the Spanish Ministry of Science, Innovation and Universities (MICINN) [SAF2017-84324-C2-1-R]; Institute of Health Carlos III (ISCIII) [PI18/00256, PIC18/00014, ICI19/00039, and PI19/01788], and cofunded by European Union (ERDF/ESF) - A way to build Europe. This work has also been funded by the Sociedad Española de Cardiología and by the Call for Expression of Interest (EoI) for Collaborative Projects on Regenerative Medicine 2019 of Center for Regenerative Medicine of Barcelona (CMR[B]). The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product, A Spanish Experience

  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Coll-Bonet, Ruth|||0000-0003-0174-379X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
A systematic and ordered product development program, in compliance with current quality and regulatory standards, increases the likelihood of yielding a successful advanced therapy medicinal product (ATMP) for clinical use as safe and effective therapy. As this is a novel field, little accurate information is available regarding the steps to be followed, and the information to be produced to support the development and use of an ATMP. Notably, successful clinical translation can be somewhat cumbersome for academic researchers. In this article, we have provided a summary of the available information, supported by our experience in Spain throughout the development of an ATMP for myocardial infarction, from the pre-clinical stage to phase I clinical trial approval.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Local administration of porcine immunomodulatory, chemotactic and angiogenic extracellular vesicles using engineered cardiac scaffolds for myocardial infarction

  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Font-Morón, Miriam|||0000-0002-4714-252X
  • Clos Sansalvador, Marta|||0000-0001-8522-7818
  • Calle Arias, Alexandra|||0000-0003-3903-5019
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Cserkóová, Adriana
  • Morancho, Anna|||0000-0001-9059-3206
  • Ramírez de Paz, Miguel Ángel|||0000-0002-5868-2134
  • Rosell Novel, Anna|||0000-0003-1082-3599
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Rudilla, F..
The administration of extracellular vesicles (EV) from mesenchymal stromal cells (MSC) is a promising cell-free nanotherapy for tissue repair after myocardial infarction (MI). However, the optimal EV delivery strategy remains undetermined. Here, we designed a novel MSC-EV delivery, using 3D scaffolds engineered from decellularised cardiac tissue as a cell-free product for cardiac repair. EV from porcine cardiac adipose tissue-derived MSC (cATMSC) were purified by size exclusion chromatography (SEC), functionally analysed and loaded to scaffolds. cATMSC-EV markedly reduced polyclonal proliferation and pro-inflammatory cytokines production (IFNγ, TNFα, IL12p40) of allogeneic PBMC. Moreover, cATMSC-EV recruited outgrowth endothelial cells (OEC) and allogeneic MSC, and promoted angiogenesis. Fluorescently labelled cATMSC-EV were mixed with peptide hydrogel, and were successfully retained in decellularised scaffolds. Then, cATMSC-EV-embedded pericardial scaffolds were administered in vivo over the ischemic myocardium in a pig model of MI. Six days from implantation, the engineered scaffold efficiently integrated into the post-infarcted myocardium. cATMSC-EV were detected within the construct and MI core, and promoted an increase in vascular density and reduction in macrophage and T cell infiltration within the damaged myocardium. The confined administration of multifunctional MSC-EV within an engineered pericardial scaffold ensures local EV dosage and release, and generates a vascularised bioactive niche for cell recruitment, engraftment and modulation of short-term post-ischemic inflammation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Wharton's jelly mesenchymal stromal cells and derived extracellular vesicles as post-myocardial infarction therapeutic toolkit, an experienced view

  • Muñoz-Domínguez, Noelia
  • Roura, Santiago|||0000-0003-4063-9661
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
Outstanding progress has been achieved in developing therapeutic options for reasonably alleviating symptoms and prolonging the lifespan of patients suffering from myocardial infarction (MI). Current treatments, however, only partially address the functional recovery of post-infarcted myocardium, which is in fact the major goal for effective primary care. In this context, we largely investigated novel cell and TE tissue engineering therapeutic approaches for cardiac repair, particu-larly using multipotent mesenchymal stromal cells (MSC) and natural extracellular matrices, from pre-clinical studies to clinical application. A further step in this field is offered by MSC-derived extracellular vesicles (EV), which are naturally released nanosized lipid bilayer-delimited particles with a key role in cell-to-cell communication. Herein, in this review, we further describe and discuss the rationale, outcomes and challenges of our evidence-based therapy approaches using Wharton's jelly MSC and derived EV in post-MI management.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Urine NMR-based TB metabolic fingerprinting for the diagnosis of TB in children

  • Comella-del-Barrio, Patricia|||0000-0002-2433-9864
  • Izquierdo-Garcia, José Luis
  • Gautier, Jacqueline
  • Doresca, Mariette Jean Coute
  • Campos-Olivas, Ramón|||0000-0002-5743-2221
  • Santiveri, Clara M.
  • Muriel-Moreno, Beatriz|||0000-0002-6683-9082
  • Prat i Aymerich, Cristina|||0000-0001-6974-9165
  • Abellana, Rosa|||0000-0003-4487-4431
  • Pérez-Porcuna, Tomás M.|||0000-0002-9951-7768
  • Cuevas, Luis E.|||0000-0002-6581-0587
  • Ruiz-Cabello, Jesús|||0000-0001-8681-5056
  • Domínguez, José|||0000-0001-7888-0309
Tuberculosis (TB) is a major cause of morbidity and mortality in children, and early diagnosis and treatment are crucial to reduce long-term morbidity and mortality. In this study, we explore whether urine nuclear magnetic resonance (NMR)-based metabolomics could be used to identify differences in the metabolic response of children with different diagnostic certainty of TB. We included 62 children with signs and symptoms of TB and 55 apparently healthy children. Six of the children with presumptive TB had bacteriologically confirmed TB, 52 children with unconfirmed TB, and 4 children with unlikely TB. Urine metabolic fingerprints were identified using high- and low-field proton NMR platforms and assessed with pattern recognition techniques such as principal components analysis and partial least squares discriminant analysis. We observed differences in the metabolic fingerprint of children with bacteriologically confirmed and unconfirmed TB compared to children with unlikely TB (p = 0.041 and p = 0.013, respectively). Moreover, children with unconfirmed TB with X-rays compatible with TB showed differences in the metabolic fingerprint compared to children with non-pathological X-rays (p = 0.009). Differences in the metabolic fingerprint in children with different diagnostic certainty of TB could contribute to a more accurate characterisation of TB in the paediatric population. The use of metabolomics could be useful to improve the prediction of TB progression and diagnosis in children.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Acellular cardiac scaffolds enriched with MSC-derived extracellular vesicles limit ventricular remodelling and exert local and systemic immunomodulation in a myocardial infarction porcine model

  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Martínez-Falguera, Daina|||0000-0002-9439-0542
  • Teis, Albert|||0000-0002-4820-0736
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Courageux, Yvan|||0000-0002-1484-2677
  • Munizaga-Larroudé, Micaela
  • Font-Morón, Miriam|||0000-0002-4714-252X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Rudilla, F..
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
Rationale: Extracellular vesicles (EVs) from mesenchymal stromal cell (MSC) are a potential therapy for cardiac healing after myocardial infarction (MI). Nevertheless, neither their efficient administration nor therapeutic mechanisms are fully elucidated. Here, we evaluate the preclinical efficacy of a tissue engineering approach to locally deliver porcine cardiac adipose tissue MSC-EV (cATMSC-EV) in an acute MI pig model. Methods: After MI by permanent ligation of the coronary artery, pigs (n = 24) were randomized to Untreated or treated groups with a decellularised pericardial scaffold filled with peptide hydrogel and cATMSC-EV purified by size exclusion chromatography (EV-Treated group) or buffer (Control group), placed over the post-infarcted myocardium. Results: After 30 days, cardiac MRI showed an improved cardiac function in EV-Treated animals, with significantly higher right ventricle ejection fraction (+20.8% in EV-Treated; p = 0.026), and less ventricle dilatation, indicating less myocardial remodelling. Scar size was reduced, with less fibrosis in the distal myocardium (-42.6% Col I in EV-Treated vs Untreated; p = 0.03), a 2-fold increase in vascular density (EV-Treated; p = 0.019) and less CCL2 transcription in the infarct core. EV-treated animals had less macrophage infiltration in the infarct core (-31.7% of CD163 + cells/field in EV-Treated; p = 0.026), but 5.8 times more expressing anti-inflammatory CD73 (p = 0.015). Systemically, locally delivered cATMSC-EV also triggered a systemic effect, doubling the circulating IL-1ra (p = 0.01), and reducing the PBMC rush 2d post-MI, the TNFα and GM-CSF levels at 30d post-MI, and modulating the CD73 + and CCR2 + monocyte populations, related to immunomodulation and fibrosis modulation. Conclusions: These results highlight the potential of cATMSC-EV in modulating hallmarks of ischemic injury for cardiac repair after MI.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical translation of mesenchymal stromal cell extracellular vesicles, Considerations on scientific rationale and production requisites

  • Courageux, Yvan|||0000-0002-1484-2677
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Roura, Santiago|||0000-0003-4063-9661
The present paper is a commentary to 'Identification and characterization of hADSC - derived exosome proteins from different isolation methods ' (Huang et al. 2021; ). Given the enthusiasm for the potential of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs), some considerations deserve attention as they move through successive stages of research and application into humans. We herein remark the prerequisite of generating that evidence ensuring a high consistency in safety, composition and biological activity of the intended MSC-EV preparations, and the suitability of disparate isolation techniques to produce efficacious EV preparations and fulfil requirements for standardized clinical-grade biomanufacturing.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Deep Learning Analyses to Delineate the Molecular Remodeling Process after Myocardial Infarction

  • Iborra Egea, Oriol|||0000-0002-7280-859X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Rudilla, F
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Ferrer-Curriu, Gemma|||0000-0002-2651-649X
  • Segú-Vergés, Cristina|||0000-0002-8215-872X
  • Mellado-Bergillos, Araceli
  • Gomez-Puchades, Pol
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Specific proteins and processes have been identified in post-myocardial infarction (MI) pathological remodeling, but a comprehensive understanding of the complete molecular evolution is lacking. We generated microarray data from swine heart biopsies at baseline and 6, 30, and 45 days after infarction to feed machine-learning algorithms. We cross-validated the results using available clinical and experimental information. MI progression was accompanied by the regulation of adipogenesis, fatty acid metabolism, and epithelial-mesenchymal transition. The infarct core region was enriched in processes related to muscle contraction and membrane depolarization. Angiogenesis was among the first morphogenic responses detected as being sustained over time, but other processes suggesting post-ischemic recapitulation of embryogenic processes were also observed. Finally, protein-triggering analysis established the key genes mediating each process at each time point, as well as the complete adverse remodeling response. We modeled the behaviors of these genes, generating a description of the integrative mechanism of action for MI progression. This mechanistic analysis overlapped at different time points; the common pathways between the source proteins and cardiac remodeling involved IGF1R, RAF1, KPCA, JUN, and PTN11 as modulators. Thus, our data delineate a structured and comprehensive picture of the molecular remodeling process, identify new potential biomarkers or therapeutic targets, and establish therapeutic windows during disease progression.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Circulating virome and inflammatory proteome in patients with ST-elevation myocardial infarction and primary ventricular fibrillation

  • Oliveras, Teresa
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Garcia Garcia, Cosme|||0000-0001-6330-1677
  • Cserkóová, Adriana
  • Rueda, Ferran|||0000-0001-5464-4870
  • Labata, Carlos|||0000-0002-4505-0787
  • Ferrer Vinardel, Marc|||0000-0002-1283-8578
  • Montero, Santiago|||0000-0002-0984-3472
  • El Ouaddi, Nabil|||0000-0002-5980-8915
  • Martínez, Maria José
  • Roura, Santiago|||0000-0003-4063-9661
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Primary ventricular fibrillation (PVF) is a life-threatening complication of ST-segment elevation myocardial infarction (STEMI). It is unclear what roles viral infection and/or systemic inflammation may play as underlying triggers of PVF, as a second hit in the context of acute ischaemia. Here we aimed to evaluate whether the circulating virome and inflammatory proteome were associated with PVF development in patients with STEMI. Blood samples were obtained from non-PVF and PVF STEMI patients at the time of primary PCI, and from non-STEMI healthy controls. The virome profile was analysed using VirCapSeq-VERT (Virome Capture Sequencing Platform for Vertebrate Viruses), a sequencing platform targeting viral taxa of 342,438 representative sequences, spanning all virus sequence records. The inflammatory proteome was explored with the Olink inflammation panel, using the Proximity Extension Assay technology. After analysing all viral taxa known to infect vertebrates, including humans, we found that non-PVF and PVF patients only significantly differed in the frequencies of viruses in the Gamma-herpesvirinae and Anelloviridae families. In particular, most showed a significantly higher relative frequency in non-PVF STEMI controls. Analysis of systemic inflammation revealed no significant differences between the inflammatory profiles of non-PVF and PVF STEMI patients. Inflammatory proteins associated with cell adhesion, chemotaxis, cellular response to cytokine stimulus, and cell activation proteins involved in immune response (IL6, IL8 CXCL-11, CCL-11, MCP3, MCP4, and ENRAGE) were significantly higher in STEMI patients than non-STEMI controls. CDCP1 and IL18-R1 were significantly higher in PVF patients compared to healthy subjects, but not compared to non-PVF patients. The circulating virome and systemic inflammation were not associated with increased risk of PVF development in acute STEMI. Accordingly, novel strategies are needed to elucidate putative triggers of PVF in the setting of acute ischaemia, in order to reduce STEMI-driven sudden death burden.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Implantation of a double allogeneic human engineered tissue graft on damaged heart, insights from the PERISCOPE phase I clinical trial

  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Cámara, Maria-Luisa|||0000-0002-5204-1459
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Cediel, Germán|||0000-0001-9667-7507
  • Rodríguez Gómez, Luciano
  • Teis, Albert|||0000-0002-4820-0736
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Ferrer-Curriu, Gemma|||0000-0002-2651-649X
  • Roura, Santiago|||0000-0003-4063-9661
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Bisbal, Felipe|||0000-0002-4843-7063
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Vilarrodona, Ana|||0000-0001-6984-1834
  • Muñoz-Guijosa, Christian|||0000-0002-0272-1704
  • Querol, Sergi|||0000-0002-1105-8633
Background: In preclinical studies, the use of double allogeneic grafts has shown promising results in promoting tissue revascularization, reducing infarct size, preventing adverse remodelling and fibrosis, and ultimately enhancing cardiac function. Building upon these findings, the safety of PeriCord, an engineered tissue graft consisting of a decellularised pericardial matrix and umbilical cord Wharton's jelly mesenchymal stromal cells, was evaluated in the PERISCOPE Phase I clinical trial (NCT03798353), marking its first application in human subjects. Methods: This was a double-blind, single-centre trial that enrolled patients with non-acute myocardial infarction eligible for surgical revascularization. Seven patients were implanted with PeriCord while five served as controls. Findings: Patients who received PeriCord showed no adverse effects during post-operative phase and one-year follow-up. No significant changes in secondary outcomes, such as quality of life or cardiac function, were found in patients who received PeriCord. However, PeriCord did modulate the kinetics of circulating monocytes involved in post-infarction myocardial repair towards non-classical inflammation-resolving macrophages, as well as levels of monocyte chemoattractants and the prognostic marker Meteorin-like in plasma following treatment. Interpretation: In summary, the PeriCord graft has exhibited a safe profile and notable immunomodulatory properties. Nevertheless, further research is required to fully unlock its potential as a platform for managing inflammatory-related pathologies.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Local administration of porcine immunomodulatory, chemotactic and angiogenic extracellular vesicles using engineered cardiac scaffolds for myocardial infarction

  • Moron-Font, Miriam
  • Clos-Sansalvador, Marta
  • Calle, Alexandra
  • Morancho Retana, Anna
  • Rosell Novel, Anna
  • Monguió-Tortajada, Marta
  • Prat-Vidal, Cristina
  • Gastelurrutia, Paloma
Ingeniería de tejido cardíaco; Exosomas; Infiltración, Enginyeria de teixits cardíacs; Exosomes; Infiltració, Cardiac tissue engineering; Exosomes; Infiltration, The administration of extracellular vesicles (EV) from mesenchymal stromal cells (MSC) is a promising cell-free nanotherapy for tissue repair after myocardial infarction (MI). However, the optimal EV delivery strategy remains undetermined. Here, we designed a novel MSC-EV delivery, using 3D scaffolds engineered from decellularised cardiac tissue as a cell-free product for cardiac repair. EV from porcine cardiac adipose tissue-derived MSC (cATMSC) were purified by size exclusion chromatography (SEC), functionally analysed and loaded to scaffolds. cATMSC-EV markedly reduced polyclonal proliferation and pro-inflammatory cytokines production (IFNγ, TNFα, IL12p40) of allogeneic PBMC. Moreover, cATMSC-EV recruited outgrowth endothelial cells (OEC) and allogeneic MSC, and promoted angiogenesis. Fluorescently labelled cATMSC-EV were mixed with peptide hydrogel, and were successfully retained in decellularised scaffolds. Then, cATMSC-EV-embedded pericardial scaffolds were administered in vivo over the ischemic myocardium in a pig model of MI. Six days from implantation, the engineered scaffold efficiently integrated into the post-infarcted myocardium. cATMSC-EV were detected within the construct and MI core, and promoted an increase in vascular density and reduction in macrophage and T cell infiltration within the damaged myocardium. The confined administration of multifunctional MSC-EV within an engineered pericardial scaffold ensures local EV dosage and release, and generates a vascularised bioactive niche for cell recruitment, engraftment and modulation of short-term post-ischemic inflammation., This work was supported in part by grants from Fundació la Marató de TV3 (201516-10, 201502-30), the PERIS (SLT002/16/00234) and SGR programmes (2017-SGR-301 REMAR Group, 2017-SGR-1427 and 2017-SGR-483 ICREC Group) from the Generalitat de Catalunya, the Spanish Ministry of Economy and Competitiveness-MICINN (SAF2017-84324-C2-1-R; PID2019-110137RB-I00; PID2019-107145RB-I00), Instituto de Salud Carlos III (PI17/01487, PIC18/00014, ICI19/00039, PI18/00256, PI18/01227, and ICI20/00135), ISCIII-REDinREN (RD16/0009 Feder Funds), Red de Terapia Celular-TerCel (RD16/0011/0006), CIBER Cardiovascular (CB16/11/00403) projects as a part of the Plan Nacional de I + D + I, and it was co-funded by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER), AGAUR (2019PROD00122), Sociedad Española de Cardiología, Societat Catalana de Cardiologia, PCMR[C] and EoI Collaborative Projects on Regenerative Medicine 2019, and Institut Català de Salut (ICS). PG is sponsored by the PERIS (SLT002/16/00209) from the Generalitat de Catalunya. AR is supported by the Miguel Servet program (CPII15/00003) and research grants (PI16/00981) from the Instituto de Salud Carlos III, and co-financed by the European Regional Development Fund. FEB is a researcher from Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, supported by the Health Department of the Catalan Government (Generalitat de Catalunya).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience

  • Vives Armengol, Joaquim
  • Coll, Ruth
  • Gálvez-Montón, Carolina
  • Prat-Vidal, Cristina
  • Gastelurrutia, Paloma
  • Bayes-Genis, Antoni
Medicament de teràpia avançada; Medicament en investigació; Translacional (regulació), Medicamento de terapia avanzada; Medicamento en investigación; Traslacional (regulación), Advanced therapy medicinal product; Investigational medicinal product; Translational (regulation), A systematic and ordered product development program, in compliance with current quality and regulatory standards, increases the likelihood of yielding a successful advanced therapy medicinal product (ATMP) for clinical use as safe and effective therapy. As this is a novel field, little accurate information is available regarding the steps to be followed, and the information to be produced to support the development and use of an ATMP. Notably, successful clinical translation can be somewhat cumbersome for academic researchers. In this article, we have provided a summary of the available information, supported by our experience in Spain throughout the development of an ATMP for myocardial infarction, from the pre-clinical stage to phase I clinical trial approval., This work was supported by the Spanish Cell Therapy Network (TerCel) [RD16/0011/0006 and RD16/0011/0028]; and CIBER Cardiovascular [CB16/11/00403] projects, as a part of the National R&D&I Plan, and was co-funded by the ISCIII-Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (ERDF); the Government of Catalonia: Agency for Management of University and Research Grants (AGAUR) [2017-SGR-483 and 2017-SGR-719], PERIS Program (Health Department) [SLT002/16/00234 and SLT002/16/00209] and CERCA Program; La Caixa Banking Foundation; grants from the Spanish Ministry of Science, Innovation and Universities (MICINN) [SAF2017-84324-C2-1-R]; Institute of Health Carlos III (ISCIII) [PI18/00256, PIC18/00014, ICI19/00039, and PI19/01788], and cofunded by European Union (ERDF/ESF) - A way to build Europe. This work has also been funded by the Sociedad Española de Cardiología and by the Call for Expression of Interest (EoI) for Collaborative Projects on Regenerative Medicine 2019 of Center for Regenerative Medicine of Barcelona (CMR[B]). The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.